Skip to main content

Table 4 Comparison of the serological findings between patients experiencing an adverse reaction (AR) to immunotherapy and those without complications (NC)

From: Anaphylactic reactions in the build-up phase of rush immunotherapy for bee venom allergy in pediatric patients: a single-center experience

 

All patients

AR

NC

 

No. of patients

19

3

16

P

sIgE honey bee venom [kU/l] m (± SD)

(n = 19)

38.1 (± 36.3)

(n = 3)

82.7 (± 15.3)

(n = 16)

29.7 (± 14.0)

0.019*

Api m1 [kU/l] m (± SD)

(n = 17)

13.8 (± 24.3)

(n = 3)

29.3 (± 10.2)

(n = 14)

10.5 (± 14.0)

0.253

Api m3 [kU/l] m (± SD)

(n = 16)

8.4 (± 7.9)

(n = 2)

22.3 (± 1.9)

(n = 14)

6.4 (± 8.9)

0.005**

Api m10 [kU/l] m (± SD)

(n = 18)

20.2 (± 33.5)

(n = 3)

38.6 (± 43.5)

(n = 15)

16.5 (± 35.1)

0.326

Serum tryptase [μg/l] m (± SD)

(n = 14)

3.6 (± 2.6)

(n = 1)

6.2 (± 0)

(n = 13)

3.4 (± 2.2)

0.348

  1. For the different groups the respective averages, the minimum, the maximum and the standard deviation for total IgE, Api m1, Api m3, Api m10 are indicated. The units are indicated in square brackets. *p < 0.05, **p < 0.01, ***p < 0.001
  2. AR patients experiencing an adverse reaction to immunotherapy, NC patients undergoing immunotherapy without complications, No. number, SD standard deviation, m mean
Back to article page

Clinical and Molecular Allergy

ISSN: 1476-7961

Contact us